Latest Revenue Growth News

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

Kip McGrath Education Centres Ltd reported solid FY25 financial results with revenue and profit growth driven by franchise expansion and premium tutoring offerings. The company anticipates continued revenue growth and improved profitability in FY26 despite flat lesson volumes.

Intelligent Monitoring Group Limited (IMG) reported a 44% revenue surge to $174.9 million in FY25, driven by four key acquisitions and organic growth, while investing heavily in AI-powered video monitoring technology.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Kip McGrath Education Centres reported solid FY25 growth in revenue and EBITDA from continuing operations, marked by a strategic exit from the USA and a new share buy-back program.

SKS Technologies has reported a remarkable near doubling of revenue to $261.7 million in FY25, driven by strong growth in data centre projects and traditional markets. The company’s robust order book and expanded bank facilities position it well for continued growth in FY26.

SKS Technologies has delivered a remarkable 92% revenue surge in FY25, driven by its data centre strategy and traditional business growth, while expanding bank facilities and forecasting $300 million revenue for FY26.

Calix Limited reported a 17% rise in product and services revenue for FY25, driven by its Magnesia and Leilac businesses, alongside a 23% reduction in operating expenses. The company extended its cash runway to 18 months, supported by a $21 million equity raise, while progressing key decarbonisation projects.

Integral Diagnostics (IDX) reported a robust FY25 with 33.7% revenue growth and operating EBITDA margin expansion, driven by the Capitol merger and organic growth. The company exceeded synergy expectations and outlined a confident outlook amid favourable industry tailwinds.

Calix Limited reported solid FY25 results with 17% growth in product revenue, a 23% cut in operating costs, and an extended 18-month cash runway, while progressing key decarbonisation projects.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.